Organogenesis Holdings Stock Analysis
| ORGO Stock | USD 3.73 0.01 0.27% |
IPO Date 5th of January 2017 | 200 Day MA 4.3738 | 50 Day MA 4.4864 | Beta 1.402 |
Organogenesis Holdings holds a debt-to-equity ratio of 0.517. At this time, Organogenesis Holdings' Short and Long Term Debt Total is very stable compared to the past year. As of the 14th of February 2026, Long Term Debt Total is likely to grow to about 76.6 M, while Long Term Debt is likely to drop about 65.7 M. With a high degree of financial leverage come high-interest payments, which usually reduce Organogenesis Holdings' Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Organogenesis Holdings' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Organogenesis Holdings' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Organogenesis Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Organogenesis Holdings' stakeholders.
For many companies, including Organogenesis Holdings, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Organogenesis Holdings, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Organogenesis Holdings' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 1.8679 | Enterprise Value Ebitda 198.1589 | Price Sales 1.0175 | Shares Float 55.9 M | Wall Street Target Price 8.5 |
Organogenesis Holdings is undervalued with Real Value of 4.89 and Target Price of 8.5. The main objective of Organogenesis Holdings stock analysis is to determine its intrinsic value, which is an estimate of what Organogenesis Holdings is worth, separate from its market price. There are two main types of Organogenesis Holdings' stock analysis: fundamental analysis and technical analysis.
The Organogenesis Holdings stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Organogenesis Holdings is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Organogenesis Stock trading window is adjusted to America/New York timezone.
Organogenesis | Build AI portfolio with Organogenesis Stock |
Organogenesis Stock Analysis Notes
About 47.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.87. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Organogenesis Holdings recorded a loss per share of 0.08. The entity had not issued any dividends in recent years. Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company was founded in 1985 and is headquartered in Canton, Massachusetts. Organogenesis Holdings operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 950 people. To find out more about Organogenesis Holdings contact Gary Sr at 781 575 0775 or learn more at https://organogenesis.com.Organogenesis Holdings Quarterly Total Revenue |
|
Organogenesis Holdings Investment Alerts
| Organogenesis Holdings generated a negative expected return over the last 90 days | |
| Organogenesis Holdings has high historical volatility and very poor performance | |
| Organogenesis Holdings has a strong financial position based on the latest SEC filings | |
| About 47.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from globenewswire.com: INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of InvestorsofOrganogenesis Holdings Inc. - ORGO |
Organogenesis Largest EPS Surprises
Earnings surprises can significantly impact Organogenesis Holdings' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-09 | 2024-03-31 | -0.03 | -0.02 | 0.01 | 33 | ||
2023-11-09 | 2023-09-30 | 0.01 | 0.02 | 0.01 | 100 | ||
2023-08-09 | 2023-06-30 | 0.03 | 0.04 | 0.01 | 33 |
Organogenesis Holdings Environmental, Social, and Governance (ESG) Scores
Organogenesis Holdings' ESG score is a quantitative measure that evaluates Organogenesis Holdings' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Organogenesis Holdings' operations that may have significant financial implications and affect Organogenesis Holdings' stock price as well as guide investors towards more socially responsible investments.
Organogenesis Stock Institutional Investors
| Shares | Renaissance Technologies Corp | 2025-06-30 | 803.9 K | Northern Trust Corp | 2025-06-30 | 788.2 K | Aqr Capital Management Llc | 2025-06-30 | 717.1 K | D. E. Shaw & Co Lp | 2025-06-30 | 613.1 K | Connor Clark & Lunn Inv Mgmt Ltd | 2025-06-30 | 593.2 K | State Of Wisconsin Investment Board | 2025-06-30 | 527.2 K | Ubs Group Ag | 2025-06-30 | 499.4 K | Bank Of America Corp | 2025-06-30 | 480.8 K | Wellington Management Company Llp | 2025-06-30 | 419.4 K | Soleus Capital Management, L.p. | 2025-06-30 | 12.3 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 12.1 M |
Organogenesis Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 473.38 M.Organogenesis Profitablity
| Last Reported | Projected for Next Year |
Management Efficiency
At this time, Organogenesis Holdings' Return On Tangible Assets are very stable compared to the past year. As of the 14th of February 2026, Return On Assets is likely to grow to 0, while Return On Capital Employed is likely to drop (0). At this time, Organogenesis Holdings' Fixed Asset Turnover is very stable compared to the past year. As of the 14th of February 2026, Return On Assets is likely to grow to 0, while Total Assets are likely to drop about 315.2 M. Organogenesis Holdings' management efficiency ratios could be used to measure how well Organogenesis Holdings manages its routine affairs as well as how well it operates its assets and liabilities.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.37 | 6.26 | |
| Tangible Book Value Per Share | 3.01 | 5.86 | |
| Enterprise Value Over EBITDA | 18.79 | 19.73 | |
| Price Book Value Ratio | 1.26 | 1.19 | |
| Enterprise Value Multiple | 18.79 | 19.73 | |
| Price Fair Value | 1.26 | 1.19 | |
| Enterprise Value | 378.5 M | 707.3 M |
At Organogenesis Holdings, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Technical Drivers
As of the 14th of February 2026, Organogenesis Holdings holds the Variance of 13.5, risk adjusted performance of (0.16), and Coefficient Of Variation of (470.80). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Organogenesis Holdings, as well as the relationship between them.Organogenesis Holdings Price Movement Analysis
The output start index for this execution was one with a total number of output elements of sixty. The Extended Parabolic SAR indicator is used to determine the direction of Organogenesis Holdings's momentum and the point in time when it has higher than normal probability of directional change. It has more input parameters than standard Parabolic SAR indicator.
Organogenesis Holdings Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Organogenesis Holdings insiders, such as employees or executives, is commonly permitted as long as it does not rely on Organogenesis Holdings' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Organogenesis Holdings insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Organogenesis Holdings Outstanding Bonds
Organogenesis Holdings issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Organogenesis Holdings uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Organogenesis bonds can be classified according to their maturity, which is the date when Organogenesis Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| US68622TAB70 Corp BondUS68622TAB70 | View | |
| US68622TAA97 Corp BondUS68622TAA97 | View |
Organogenesis Holdings Predictive Daily Indicators
Organogenesis Holdings intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Organogenesis Holdings stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 24166.56 | |||
| Daily Balance Of Power | (0.06) | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 3.8 | |||
| Day Typical Price | 3.78 | |||
| Price Action Indicator | (0.07) | |||
| Period Momentum Indicator | (0.01) |
Organogenesis Holdings Forecast Models
Organogenesis Holdings' time-series forecasting models are one of many Organogenesis Holdings' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Organogenesis Holdings' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Organogenesis Holdings Bond Ratings
Organogenesis Holdings financial ratings play a critical role in determining how much Organogenesis Holdings have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Organogenesis Holdings' borrowing costs.| Piotroski F Score | 7 | Strong | View |
| Beneish M Score | (0.89) | Possible Manipulator | View |
Organogenesis Holdings Debt to Cash Allocation
As Organogenesis Holdings follows its natural business cycle, the capital allocation decisions will not magically go away. Organogenesis Holdings' decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
Organogenesis Holdings currently holds 43.31 M in liabilities with Debt to Equity (D/E) ratio of 0.52, which is about average as compared to similar companies. Organogenesis Holdings has a current ratio of 2.57, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Organogenesis Holdings' use of debt, we should always consider it together with its cash and equity.Organogenesis Holdings Total Assets Over Time
Organogenesis Holdings Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Organogenesis Holdings uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Organogenesis Holdings Debt Ratio | 9.5 |
Organogenesis Holdings Corporate Bonds Issued
Organogenesis Long Term Debt
Long Term Debt |
|
About Organogenesis Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Organogenesis Holdings prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Organogenesis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Organogenesis Holdings. By using and applying Organogenesis Stock analysis, traders can create a robust methodology for identifying Organogenesis entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.01) | (0.01) | |
| Gross Profit Margin | 0.68 | 0.58 |
Current Organogenesis Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Organogenesis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Organogenesis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 8.5 | Strong Buy | 4 | Odds |
Most Organogenesis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Organogenesis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Organogenesis Holdings, talking to its executives and customers, or listening to Organogenesis conference calls.
Organogenesis Stock Analysis Indicators
Organogenesis Holdings stock analysis indicators help investors evaluate how Organogenesis Holdings stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Organogenesis Holdings shares will generate the highest return on investment. By understating and applying Organogenesis Holdings stock analysis, traders can identify Organogenesis Holdings position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 104.3 M | |
| Total Stockholder Equity | 385.3 M | |
| Capital Lease Obligations | 43.3 M | |
| Property Plant And Equipment Net | 126.2 M | |
| Cash And Short Term Investments | 135.6 M | |
| Cash | 135.6 M | |
| 50 Day M A | 4.4864 | |
| Net Interest Income | -1.5 M | |
| Total Current Liabilities | 77.5 M | |
| Forward Price Earnings | 12.3153 | |
| Investments | -10 M | |
| Interest Expense | 1.5 M | |
| Stock Based Compensation | 10.6 M | |
| Common Stock Shares Outstanding | 131.7 M | |
| Total Cashflows From Investing Activities | -10 M | |
| Tax Provision | -3.7 M | |
| Quarterly Earnings Growth Y O Y | 0.222 | |
| Accounts Payable | 28.9 M | |
| Net Debt | -92.3 M | |
| Other Operating Expenses | 483.3 M | |
| Non Current Assets Total | 211.9 M | |
| Liabilities And Stockholders Equity | 497.9 M | |
| Non Currrent Assets Other | 5 M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Will Biotechnology sector continue expanding? Could Organogenesis diversify its offerings? Factors like these will boost the valuation of Organogenesis Holdings. Anticipated expansion of Organogenesis directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Organogenesis Holdings data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.222 | Earnings Share (0.08) | Revenue Per Share | Quarterly Revenue Growth 0.31 | Return On Assets |
Investors evaluate Organogenesis Holdings using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Organogenesis Holdings' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Organogenesis Holdings' market price to deviate significantly from intrinsic value.
It's important to distinguish between Organogenesis Holdings' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Organogenesis Holdings should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Organogenesis Holdings' market price signifies the transaction level at which participants voluntarily complete trades.